Revitope Oncology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Revitope Oncology is pioneering a modular, precision immunotherapy platform to address the critical safety challenge of on-target, off-tumor toxicity in cancer treatment. Its proprietary Two GATE™ (Guided Antibody Tumor Engager) technology utilizes a dual-antigen 'AND' gate and tumor-specific protease activation to conditionally engage T cells only at the tumor site. The company has advanced its lead program, REV-403 (targeting EGFR and PDL1), into Phase 1 trials and has built a broader preclinical pipeline through internal efforts and strategic collaborations with partners like Junshi Biosciences and Genmab. Founded in 2013 and based in Cambridge, Massachusetts, Revitope is a private, pre-revenue biotech focused on expanding the therapeutic window for immuno-oncology drugs.

Oncology

Technology Platform

Two GATE™ (Guided Antibody Tumor Engager) Technology Platform: A modular, two-component system for creating 'gated' immunotherapies. It uses a dual-antigen 'AND' gate for targeting, tumor-microenvironment-specific protease activation, and conditional assembly of T-cell engagers to focus immune responses exclusively on tumors.

Opportunities

The primary opportunity is to address the massive unmet need for safer, more effective immunotherapies for solid tumors by overcoming dose-limiting 'on-target, off-tumor' toxicity.

Success could enable the targeting of previously undruggable antigen combinations and expand treatable patient populations.

The modular platform also allows for expansion into other immune-modulating modalities beyond T-cell engagers.

Risk Factors

Key risks include the failure of the complex Two GATE™ mechanism to validate clinically in terms of safety and efficacy, particularly for the lead asset REV-403.

The company also faces significant competition from other next-generation conditional immunotherapy platforms, technical and manufacturing challenges associated with two-component biologics, and financing risk as a private, pre-revenue entity.

Competitive Landscape

Revitope competes in the rapidly evolving field of conditional and precision immuno-oncology. Competitors include companies developing protease-activated 'masked' antibodies (e.g., CytomX Therapeutics), logic-gated CAR-T therapies, and other bispecific antibody platforms with safety switches. Large pharma companies with extensive IO portfolios also represent competitive and potential acquisitive forces.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →